# Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

> **NCT02520778** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 27 (actual)

## Conditions studied

- Advanced Lung Non-Squamous Non-Small Cell Carcinoma
- Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
- Stage III Lung Non-Small Cell Cancer AJCC v7
- Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Stage IIIB Lung Non-Small Cell Cancer AJCC v7
- Stage IV Lung Non-Small Cell Cancer AJCC v7

## Interventions

- **DRUG:** Navitoclax
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT02520778
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-30
- **Primary completion:** 2022-10-26
- **Final completion:** 2023-12-04
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2024-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02520778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02520778, "Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02520778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*